Literature DB >> 7712205

Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo.

J Hudson1, A C Granholm, G A Gerhardt, M A Henry, A Hoffman, P Biddle, N S Leela, L Mackerlova, J D Lile, F Collins.   

Abstract

Recently, a novel glial cell line-derived neurotrophic factor (GDNF) has been identified, cloned, and shown to have potent survival- and growth-promoting activity on fetal rat midbrain dopaminergic neurons in cell culture. In this study, we document marked and long-lasting effects on adult rat midbrain dopaminergic neurons in vivo after intracranial administration. A single injection of this factor into the substantia nigra elicited a dose-dependent increase in both spontaneous and amphetamine-induced motor activity, and a decrease in food consumption, lasting 7-10 days. Using immunocytochemistry, we found sprouting of tyrosine hydroxylase-positive neurites towards the injection site, and increased tyrosine hydroxylase immunoreactivity of the ipsilateral striatum was produced by GDNF. There was also a marked and dose-dependent increase in dopamine turnover in the substantia nigra and striatum, and in ipsilateral dopamine levels in the substantia nigra. Little or no effects of GDNF were seen on norepinephrine or serotonin levels. The neurochemical changes on dopaminergic afferents persist for at least 3 weeks after a single intracranial injection of 10 micrograms. Taken together, these data suggest that this glial cell line-derived factor has a potent influence on adult rat dopamine neurons and may have a potentially important role as a trophic factor for these neurons.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7712205     DOI: 10.1016/0361-9230(94)00224-o

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  61 in total

1.  Is GDNF beneficial in Parkinson disease?

Authors:  Barry J Hoffer; Brandon K Harvey
Journal:  Nat Rev Neurol       Date:  2011-09-20       Impact factor: 42.937

2.  GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis.

Authors:  C M Kearns; W A Cass; K Smoot; R Kryscio; D M Gash
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

3.  Evoked dopamine overflow is augmented in the striatum of calcitriol treated rats.

Authors:  Wayne A Cass; Laura E Peters; Anita M Fletcher; David M Yurek
Journal:  Neurochem Int       Date:  2011-11-22       Impact factor: 3.921

4.  Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum.

Authors:  Wayne A Cass; Laura E Peters
Journal:  Neurochem Int       Date:  2010-07-06       Impact factor: 3.921

5.  Endogenous GDNF in ventral tegmental area and nucleus accumbens does not play a role in the incubation of heroin craving.

Authors:  Mikko Airavaara; Charles L Pickens; Anna L Stern; Kristina A Wihbey; Brandon K Harvey; Jennifer M Bossert; Qing-Rong Liu; Barry J Hoffer; Yavin Shaham
Journal:  Addict Biol       Date:  2010-12-23       Impact factor: 4.280

6.  Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine.

Authors:  Michael P Smith; Anita Fletcher-Turner; David M Yurek; Wayne A Cass
Journal:  Neurochem Res       Date:  2006-04       Impact factor: 3.996

7.  Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease.

Authors:  J Garcia de Yebenes; J Yebenes; M A Mena
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

8.  Nigral GFRα1 infusion in aged rats increases locomotor activity, nigral tyrosine hydroxylase, and dopamine content in synchronicity.

Authors:  Brandon S Pruett; Michael F Salvatore
Journal:  Mol Neurobiol       Date:  2013-01-16       Impact factor: 5.590

9.  Long distance directional growth of dopaminergic axons along pathways of netrin-1 and GDNF.

Authors:  C Zhang; Y Jin; K S Ziemba; A M Fletcher; B Ghosh; E Truit; D M Yurek; G M Smith
Journal:  Exp Neurol       Date:  2013-10-04       Impact factor: 5.330

Review 10.  Neurotrophic factors for the investigation and treatment of movement disorders.

Authors:  Justo Garcia De Yébenes; Marina Sánchez; Maria Angeles Mena
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.